DOT1L (DOT1 like histone H3K79 methyltransferase)
2016-08-01 Kathrin M. Bernt  , Tobias Neff   AffiliationPediatric Hematology\\\/Oncology\\\/BMT, University of Colorado, Aurora, CO, USA; [email protected]; [email protected]
Identity

Abstract
DOT1L is a histone lysine methyltransferase (KMT). It is the only known methyltransferase for lysine residue 79 on histone 3 (H3K79). The active site of DOT1L bears more homology to the active site in Protein Arginin Methyl Transferases (PRMTs) than the SET domain of other KMTs. DOT1L has important roles in normal development and cellular differentiation. DOT1L plays especially important roles in normal hematopoiesis and in leukemia. Initially characterized as a therapeutic target in MLL-rearranged acute leukemias, recent data suggest that DOT1L is also therapeutic target in other molecular subtypes of acute leukemia and in selected solid tumors. A phase 1 clinical trial of a small molecule inhibitor of Dot1L has been described, with encouraging responses being reported.
DNA/RNA
Description
Transcription
Proteins

Description
Localisation
Function
The biochemical function of yeast DOT1 and mammalian DOT1L is the methylation of the histone 3 core lysine 79 residue (Feng et al., 2002; Lacoste et al., 2002; Ng et al., 2002; van Leeuwen et al., 2002). DOT1 and hDOT1L methylate nucleosomal substrates, but not free histone H3. They have homology with arginine methyltransferases, but do not contain a SET-domain typical of most lysine methyl-transferases.
Lysine K79me2/3 is thought to be associated with expressed genes. Some evidence suggests antagonism between K79me2/3 and histone 3 lysine 9 methylation-mediated gene silencing mediated by SIRT1 and SUV39H1, which is compatible with prior findings in yeast (Ehrentraut et al., 2011). H3K79 methylation is thought to be linked to cell cycle regulation (Schulze et al., 2009) and to the DNA damage response (Giannattasio et al., 2005).
In bone marrow and leukemia, DOT1L is thought to be important in the regulation of, among other genes, the late HOXA cluster (Bernt et al., 2011; Riedel et al., 2016). In prostate cancer there is evidence for a link between androgen receptor signaling and DOT1L (Yang et al., 2013).
Homology
Mutations
Note
Germinal
Somatic
Implicated in
Subsequent work has confirmed this concept, and has suggested additional cancers that might potentially be therapeutically targeted by inhibiting DOT1L. A growing number of small molecule inhibitors of DOT1L have been reported (Chen, S. et al., 2016; Luo et al., 2016; Spurr et al., 2016; Yao et al., 2011; Yi et al., 2015; Yu et al., 2013). Most of them are at the stage of a chemical probe, but the first compound to be reported (Daigle et al., 2013; Daigle et al., 2011) has shown encouraging evidence of efficacy in a Phase 1 clinical trial.
Article Bibliography
| Pubmed ID | Last Year | Title | Authors |
|---|---|---|---|
| 25006183 | 2014 | DOT1L-HES6 fusion drives androgen independent growth in prostate cancer. | Annala M et al |
| 21741597 | 2011 | MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. | Bernt KM et al |
| 23138183 | 2013 | Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. | Chen L et al |
| 26914852 | 2016 | Identification of Novel Disruptor of Telomeric Silencing 1-like (DOT1L) Inhibitors through Structure-Based Virtual Screening and Biological Assays. | Chen S et al |
| 21741596 | 2011 | Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. | Daigle SR et al |
| 23361907 | 2013 | Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. | Deshpande AJ et al |
| 25576241 | 2015 | Exome sequencing reveals three novel candidate predisposition genes for diffuse gastric cancer. | Donner I et al |
| 21896656 | 2011 | Structural basis for the role of the Sir3 AAA+ domain in silencing: interaction with Sir4 and unmethylated histone H3K79. | Ehrentraut S et al |
| 12123582 | 2002 | Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. | Feng Q et al |
| 15632126 | 2005 | The DNA damage checkpoint response requires histone H2B ubiquitination by Rad6-Bre1 and H3 methylation by Dot1. | Giannattasio M et al |
| 27535106 | 2016 | Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. | Kühn MW et al |
| 12097318 | 2002 | Disruptor of telomeric silencing-1 is a chromatin-specific histone H3 methyltransferase. | Lacoste N et al |
| 27344947 | 2016 | Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development. | Lu R et al |
| 27434826 | 2016 | Identification of phenoxyacetamide derivatives as novel DOT1L inhibitors via docking screening and molecular dynamics simulation. | Luo M et al |
| 12080090 | 2002 | Lysine methylation within the globular domain of histone H3 by Dot1 is important for telomeric silencing and Sir protein association. | Ng HH et al |
| 15851025 | 2005 | hDOT1L links histone methylation to leukemogenesis. | Okada Y et al |
| 27335278 | 2016 | DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. | Rau RE et al |
| 26927674 | 2016 | MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia. | Riedel SS et al |
| 25092143 | 2014 | Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro. | Sarkaria SM et al |
| 19682934 | 2009 | Linking cell cycle to histone modifications: SBF and H2B monoubiquitination machinery and cell-cycle regulation of H3K79 dimethylation. | Schulze JM et al |
| 15371351 | 2005 | Characterization of the grappa gene, the Drosophila histone H3 lysine 79 methyltransferase. | Shanower GA et al |
| 27485386 | 2016 | New small molecule inhibitors of histone methyl transferase DOT1L with a nitrile as a non-traditional replacement for heavy halogen atoms. | Spurr SS et al |
| 21474073 | 2011 | Dot1 and histone H3K79 methylation in natural telomeric and HM silencing. | Takahashi YH et al |
| 26728620 | 2016 | The upstreams and downstreams of H3K79 methylation by DOT1L. | Vlaming H et al |
| 23945587 | 2013 | lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. | Yang L et al |
| 21936531 | 2011 | Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies. | Yao Y et al |
| 25397901 | 2015 | Structure-guided DOT1L probe optimization by label-free ligand displacement. | Yi JS et al |
| 23433670 | 2013 | Bromo-deaza-SAH: a potent and selective DOT1L inhibitor. | Yu W et al |
| 25359765 | 2014 | Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer. | Zhang L et al |
| 14572310 | 2004 | Structure and regulation of the mDot1 gene, a mouse histone H3 methyltransferase. | Zhang W et al |
| 12086673 | 2002 | Dot1p modulates silencing in yeast by methylation of the nucleosome core. | van Leeuwen F et al |
Other Information
Locus ID:
NCBI: 84444
MIM: 607375
HGNC: 24948
Ensembl: ENSG00000104885
Variants:
dbSNP: 84444
ClinVar: 84444
TCGA: ENSG00000104885
COSMIC: DOT1L
RNA/Proteins
Expression (GTEx)
Pathways
Protein levels (Protein atlas)
PharmGKB
| Entity ID | Name | Type | Evidence | Association | PK | PD | PMIDs |
|---|---|---|---|---|---|---|---|
| PA444552 | Hypertension | Disease | ClinicalAnnotation | associated | PD | 22440088, 31327267 | |
| PA448765 | candesartan | Chemical | ClinicalAnnotation | associated | PD | 31327267 | |
| PA449899 | hydrochlorothiazide | Chemical | ClinicalAnnotation | associated | PD | 22440088 |
References
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 38072145 | 2024 | DOT1L decelerates the development of osteoporosis by inhibiting SRSF1 transcriptional activity via microRNA-181-mediated KAT2B inhibition. | 0 |
| 38172378 | 2024 | The disruptor of telomeric silencing 1-like (DOT1L) promotes peritoneal fibrosis through the upregulation and activation of protein tyrosine kinases. | 0 |
| 38865244 | 2024 | DOT1L maintains NK cell phenotype and function for optimal tumor control. | 1 |
| 38892207 | 2024 | Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic and Myeloid Leukemia. | 0 |
| 38072145 | 2024 | DOT1L decelerates the development of osteoporosis by inhibiting SRSF1 transcriptional activity via microRNA-181-mediated KAT2B inhibition. | 0 |
| 38172378 | 2024 | The disruptor of telomeric silencing 1-like (DOT1L) promotes peritoneal fibrosis through the upregulation and activation of protein tyrosine kinases. | 0 |
| 38865244 | 2024 | DOT1L maintains NK cell phenotype and function for optimal tumor control. | 1 |
| 38892207 | 2024 | Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic and Myeloid Leukemia. | 0 |
| 36017623 | 2023 | DOT1L regulates MTDH-mediated angiogenesis in triple-negative breast cancer: intermediacy of NF-κB-HIF1α axis. | 6 |
| 36183166 | 2023 | Targeting inflammatory macrophages rebuilds therapeutic efficacy of DOT1L inhibition in hepatocellular carcinoma. | 3 |
| 36318113 | 2023 | DOT1 L Regulates Ovarian Cancer Stem Cells by Activating β-catenin Signaling. | 4 |
| 36674903 | 2023 | Neuronal Dot1l Activity Acts as a Mitochondrial Gene-Repressor Associated with Human Brain Aging via H3K79 Hypermethylation. | 2 |
| 36773049 | 2023 | The effect of ITLN1, XCL2 and DOT1L variants on knee osteoarthritis risk in the Han population. | 1 |
| 37085741 | 2023 | A novel role of DOT1L in kidney diseases. | 0 |
| 37256945 | 2023 | Gain-of-function mutations in the catalytic domain of DOT1L promote lung cancer malignant phenotypes via the MAPK/ERK signaling pathway. | 3 |
Citation
Kathrin M. Bernt ; Tobias Neff
DOT1L (DOT1 like histone H3K79 methyltransferase)
Atlas Genet Cytogenet Oncol Haematol. 2016-08-01
Online version: http://atlasgeneticsoncology.org/gene/43797/dot1l
